0 93

Cited 0 times in

골관절염 환자에서 케토프로펜 지속성 제피과립(Oruvail)의 치료효과

Other Titles
 Clinical Trial of Controlled Release Ketoprofen in Patients with Osteoarthritis of Knee 
Authors
 이수곤 
Citation
 Newest Medical Journal (최신의학), Vol.40(7) : 43-48, 1997 
Journal Title
Newest Medical Journal(최신의학)
ISSN
 0529-3804 
Issue Date
1997
Abstract
We conducted a clinical study to evaluate the efficacy and safety of newly developed Controlled Release Ketoprofen for the treatment of knee osteoarthritis. We measured clini-cal variables including pain and inflammation, and laboratory variables and events of adverse drug reactions before and after oral administration of Controlled Release Ketoprofen to 25 patients with osteoarthritis. Seven patients dropped out. Total period of administration was eight weeks. Following results were obtained.
1. After eight weeks of Controlled Release Ketoprofen, we observed statistically signifi-cant improvement in pain on motion, pain on induction, swelling and tenderness.
2. The improvement of activities of daily living, pain at rest, limitation of motion, visual analogue pain scale, and morning stiffness was not statistically significant.
3. There was no significant changes on laboratory findings after eight weeks of Controlled Release Ketoprofen.
4. Adverse drug reactions were observed in cases. Adverse reactions were mild and improved with discontinuation or reduction of dose. Epigastric pain was observed in 6 out of 20 (40%) . There was no case whose stool occult blood test converted positively.
5. Overall efficacy observed by patient and physician after treatment revealed marked improvement or improvement in 70%.
In conclusion, Controlled Release Ketoprofen are effective and safe in the management of osteoarthritis of knee.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Soo Kon(이수곤)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/178057
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links